|
123 documents found matching dt:publication.
|
|
of 13
Prev
Next
|
|
|
|
Showing 1-10 of 123 documents
|
1.
Fee-For-Service Provider Manual - Authorization/IHS Referral: Chapter 6
|
Document Date:
|
19990700
|
|
Search Terms in Context:
|
Fee-For-Service Provider Manual July, 1999
A
acs Authorization/IFIS Referral
Chapter: 6
Page: 6 - 7
PRIOR AUTHORIZATION OF ACUTE SERVICES (CONT.)
H Non-emergency transportation
/ Non-emergency transportation provided by ground ambulance, air ambulance, and non-
ambulance vehicles require PA.
/ Only codes for the base rate and mileage will be prior authorized.
/ This service is not covered for ESP recipients.
H Nursing facilities
/ PA must be obtained before admission of an acute care recipient unless the recipient becomes
retroactively eligible for AHCCCS.
B No PA is required during the retro period, but the stay is subject to medical review.
/ Initial authorization will not exceed the recipient's anticipated fee-for-service enrollment period
or a medically necessary length of stay, whichever is shorter.
/ Reauthorization for continued stay is subject to concurrent utilization review by AHCCCS or its
designee.
/ AHCCCS will allow up to 90 days of nursing facility care in a contract year (1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/cta00a10
|
|
| |
2.
Sleep Disorders: Restless Legs Syndrome
|
Document Date:
|
19950400
|
|
Author:
|
Chokroverty, Sudhansu|Culebras, Antonio
|
|
Search Terms in Context:
|
pgNbr=1
u rice
erly.
tl or
ion
is-
nt
in
in
I
,,emvon Session
a-sion No. 30
S'EEp DISORDERS: RESTLESS LEGS
SYNDROME
Wednesday, May 10
2:00 PM- 3:30 PM
(Room 613/14)
Chairs: Sudhansu Cholroverty, Syracuse, NY
Antonio Culebras, Syracuse, NY
sir symp-
efficacy of alpha adrenergic agents,
mazepine, dopaminergic agents, and
444S
1 ^ :!V
Circadian Rhythm of the Restless Legs
Syndrome
emale, 42-77
,krthur 5 Walters, New Brunswick. NJ; C. Treakwalder, W. tOII Eleven used Stnemet (regular or CR) as drug of choice, 5
Chokrovert, and K Rachman, New Brunswick and used donazepam, and 1 used both. One physician with extensive
Hen'ns. ` pediatric Practice favored donidine. All respondents used both
L,.on, NJ. and Munich. Germany dopaminergic agents and
cis. Sixteen ben, adiasepiaes in treatment; 16 used
obtec:,i ( We Meant to demonstrate whether the motor and op respondents used combination treatment with
sensor% components of the restless legs syndrome (RLS) are ent+ ~mm different classes. Other medications
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/fbb00a10
|
|
| |
3.
Neurology 46
|
Document Date:
|
19960200
|
|
Author:
|
Mathew, Ninan T|Lucker, Christine
|
|
Search Terms in Context:
|
pgNbr=1
r.
m
ed
is-
ne
fi-
ar
he
nd
ke
vi-
3u
sis
by
.he
nic
in-
tin
'w-
Results. We identified 15 (23.4%) patients who developed
hemicranial migraine-like headaches. None of these 15 patients
reported similar headaches prior to implantation.
Conclusion. Our findings support the central theory and pro-
vide the most definitive proof to date that migraine syndromes
can arise from disturbed serotonergic neurotransmission within
deep brain structures.
S09-0041
2:45 Ali
Gabapentin in Migraine Prophylaxis:
A Preliminary Open Label Study
Ninan T. Mathew and Christine Lucker, Houston, TX
Objective. To assess the efficacy and safety of gabapentin in
the prophylactic treatment of migraine and transformed mi-
graine.
Background. Sodium valproate (SV) was recently shown to be
effective in migraine prophylaxis. Valproate reduces C-Fos ex-
pression in tngeminal nucleus caudalis (TNC) and blocks the
meningeal neurogeruc inflammation after noxious stimulation. A
GABA, receptor mediated mechanism is postul
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/hbb00a10
|
|
| |
4.
Grant Request: Scientific Article in Support of Epilepsy Education
|
Document Date:
|
19961212
|
|
Author:
|
Parenti, Mary A|Beck, Leigh A|Globus, Nancy J
|
|
Corporate Author:
|
Medical Education Systems Incorporated
|
|
Search Terms in Context:
|
publication in the second and third quarters of 1997.
1W09820
pgNbr=4
BUDGET NARRATIVE:
Editorial research and development of 12 scientific articles @ $12,000 per article
$144,000
Honorarium to author 12 scientific articles @ $1,000 per article
$12,000
Miscellaneous fees including Federal Express charges, permissions, etc. @ $375 per
article
$ 4.500
PROJECT TOTAL $160,500
Cost analysis per
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/vfa00a10
|
|
| |
5.
[Acknowledgement to companies for underwriting the International Workshops on COX-2 Program]
|
Document Date:
|
00000000
|
|
Corporate Author:
|
International Study Group
|
|
Search Terms in Context:
|
I H M B U TI D B A L W fl flu S H B P S OH
C O X - 2
Peter E. Lipsky, MD
Harold C. Simmons Professor
io Arthritis Research Director. Rheumatic Diseuses Division Director, Harold C. Simmons
Arthritis Restarci! Center The University of Texas Southwestern
Medical Cernerai Dallas Dallas. Texas
Steven B. Abramson, MD
Professar of Medicine
New York University School of Medicine
Chair. Department of Rheumatology
Hospital for Joint Diseases
New York. New York
Peter Brooks. MD. FRACP
Professor. Executive Dean of Health
Sciences The University oí Queensland Royal Brisbane Hospital Herston. Queensland Australia
Leslie CrofTord. MD
Assistant Professor Division of Rheumatologs University of Michigan Medical Center Ann Arbor. Michigan
Raymond N. DuBois. MD. PhD
Professor of Medicine and Ceil Biology Director of Gastroenterology
and Cancer Prevention Vanderbilt University Medical Cerner Nashville, Tennessee
Carre! A. ntzGerali. >.!!>
Professor of Medicine and Pharmacology Chair. Depanment of Pharmaco
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx00e10
|
|
| |
6.
[Acknowledgement to companies for providing unrestricted educational grants]
|
Document Date:
|
00000000
|
|
Corporate Author:
|
Steering Committee
|
|
Search Terms in Context:
|
F irsi muaniioNAi
WORKSHOP
il H
C O X -
¦ 2
Peter E. Lipsky, MD
Hamid C. Simmons Professor
in Animus Research Director, Rheumatic Diseases Division Director, Harold C. Simmons
Arthritis Research Center The University of Texas Southwestern
Medical Center at Dallas Dallas, Tesas
Steten B.Abrsinson,MD
Professor oí Medicine
New York University School of Medicine
Chair, Department of Rheumatology
Hospital for Joint Diseases
New York, New York
Peter Brooks, MD, FRACP
Professor of Medicine University of New South Wales The Associate Dean—Clinical School St- Vincent's Hospital Victoria St- Dartinghurst Sydney, Australia
Leslie Crofford, MD
Assistant Professor Division of Rheumatology University of Michigan Medical Center Ann Arbor, Michigan
Raymond N. DuBols, MD
Profesor of Medicine and Cell Biology Division of Gastroenterology Vanderbilt University Medical Center Nashville, Tennessee
David Graham, MD
Professor of Medicine Chief of Gastroenterology Baylor College of Medicine Houston, Texas
Ca
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx00k10
|
|
| |
7.
National Pharmacy Compliance News: Generic and Therapeutic Substitution
|
Document Date:
|
00000000
|
|
Page Count:
|
2
|
|
Search Terms in Context:
|
National Ph
(Applicability of the contents of articles in the National
Generic and Therapeutic Substitution
Pharmacists are often faced with decisions about whether to substitute one drug product for another. These decisions can have important clinical, economic, and legal ramifications. Until the 1970s, virtually every state had either a statute or an administrative rule strictly forbidding prescription drug substitution. Today, the situation is very different. All 50 states have drug product selection laws that allow, encourage, or mandate some form of substitution.
Two types of substitution are addressed in state statutes: generic and therapeutic. Generic substitution is the act of dispensing a different brand or unbranded drug product than the one prescribed. Generic substitution can only be done legally when the substituted products contain the same chemical entity and are bioequivalent to one another. Therapeutic substitution is the act of dispensing a therapeutic alternate (different chemical entit
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/zib37b10
|
|
| |
8.
2001 Supplement [Women's Health in Primary Care]
|
Document Date:
|
20011001
|
|
Page Count:
|
39
|
|
Search Terms in Context:
|
: The association of postmenopausal hormone therapy with breast cancer risk remains controversial, despite the publication of over 50 observational studies on this topic. Conflicting results and intense media attention on studies reporting positive associations have generated significant confusion and concern among women and their health care providers about the risks and benefits of hormone therapy
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/yub37b10
|
|
| |
9.
4thquarternews2000[1] [National Pharmacy Compliance News]
|
Document Date:
|
00000000
|
|
Page Count:
|
2
|
|
Search Terms in Context:
|
National Pharmacy
iA|>plicvil)illifv of Ihe conk'tils til article*, in fhe National Pharmacy <¦'.
Generic andTherapeutic Substitution
Pharmacists are often faced with decisions about whether to substitute one drug product for another. These decisions can have important clinical, economic, and legal ramifications. Until the 1970s, virtually every state had either a statute or an administrative rule strictly forbidding prescription drug substitution. Today, the situation is very different. All 50 states have drug product selection laws that allow, encourage, or mandate some form of substitution.
Two types of substitution are addressed in state statutes: generic and therapeutic. Generic substitution is the act of dispensing a different brand or unbranded drug product than the one prescribed. Generic substitution can only be done legally when the substituted products contain the same chemical entity and are bioequivalent to one another. Therapeutic substitution is the act of dispensing a therapeutic alternate
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ytb37b10
|
|
| |
10.
Oregon Administrative Rules Compilation Chapter 410 Department of Human Services, Office of Medical Assistance Programs Division 121 Pharmaceutical Services
|
Document Date:
|
20021015
|
|
Corporate Author:
|
Department of Human Services
|
|
Search Terms in Context:
|
I
Page 10
3
OR ADC 410.121-0040
OAR 410-121-0040
Or. Admin. r. 410-121-0040
OREGON ADMINISTRATIVE RULES COMPILATION
CHAPTER 410. DEPARTMENT OF HUMAN SERVICES, OFFICE OF MEDICAL ASSISTANCE
PROGRAMS
DIVISION 121. PHARMACEUTICAL SERVICES
Current through October 15, 2002
410-121-0040 Prior Authorization Required for Drugs and Products
(1) Prescribing practitioners are responsible for obtaining prior authorization for the following drugs and
per:
(a) Isotretinoin (Acamane) and Retinoic Acid (Retie A);
(b) Growth hormone;
(c) Oral Nutritional supplements;
(d) Antihistamirres (selected);
(e) Nasal inhalers (selected);
(f) Antifimgals (selected);
(g) Weight redaction drugs;
doses;
(h) Excessive daily
(i) Coal tar preparations;
(j) Topical antibiotics;
(k) Topical antivirals (selected);
(1) Topical t stosterome;
(m) Drugs with cosmetic indications;
(A) Emollients;
(B) Dermatologicals;
(C) Hair growth products;
(n) Proton Pump Inhibitors: Prior authorization is required after the initial eight weeks
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/wwa00a10
|
|
| |
|
Prev
Next
|
